Anticholinergic Drugs Global Market Report 2024

Anticholinergic drugs are medications that block acetylcholine's action, a neurotransmitter in the nervous system. By inhibiting acetylcholine from binding to its receptors, these drugs reduce its effects throughout the body, thereby treating conditions caused by excessive cholinergic activity.

These drugs primarily exist as synthetic, natural, and semi-synthetic compounds. Synthetic anticholinergic drugs are chemically manufactured in laboratories rather than derived from natural sources. They can be administered via different routes such as oral, parenteral, and topical applications, addressing conditions such as overactive bladder, Parkinson's disease, chronic obstructive pulmonary disease, muscle spasms, and irritable bowel syndrome. These medications are distributed through various channels including hospital pharmacies, retail pharmacies, and online platforms.

The anticholinergic drugs market research report is one of a series of new reports that provides anticholinergic drugs market statistics, including anticholinergic drugs industry global market size, regional shares, competitors with an anticholinergic drugs market share, detailed anticholinergic drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the anticholinergic drugs industry. This anticholinergic drug research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The anticholinergic drugs market size has grown strongly in recent years. It will grow from $5.4 billion in 2023 to $5.82 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The increase during the historical period can be ascribed to several factors such as a rising elderly population, higher incidence of chronic diseases, expanded healthcare infrastructure, evolving lifestyles, environmental influences, enhanced diagnostic techniques, and early disease detection.

The anticholinergic drugs market size is expected to see strong growth in the next few years. It will grow to $7.94 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period is attributed to increased healthcare spending, broader applications, heightened patient awareness and education, a growing emphasis on personalized treatment approaches, and the establishment of research centers in emerging markets. Key trends anticipated during this period include technological advancements, strategic partnerships, product innovation, the expansion of research facilities, and greater investment in the field.

The anticipated rise in chronic diseases is projected to propel the growth of the anticholinergic drugs market in the coming years. Chronic diseases are enduring conditions requiring ongoing medical care, potentially limiting daily activities and overall quality of life. Factors contributing to their prevalence include altered habits, genetic inheritance, and exposure to environmental pollutants and toxins. Anticholinergic drugs play a crucial role in managing specific chronic conditions by targeting and mitigating excessive cholinergic activity in the body. For instance, by January 2023, the National Center for Biotechnology Information (NCBI) forecasts a 99.5% increase in individuals aged 50 and older suffering from one or more chronic illnesses by 2050, rising from 71.52 million in 2020 to 142.66 million. Thus, the growing prevalence of chronic diseases is driving the expansion of the anticholinergic drugs market.

Key players in the anticholinergic drugs market are actively innovating, such as developing pre-operative medications, to strengthen their market presence. Pre-operative medications refer to drugs administered before surgical procedures to achieve specific therapeutic goals such as reducing anxiety, managing pain, inducing sedation, preventing nausea and vomiting, and providing antibiotic prophylaxis. For instance, in November 2022, Alembic Pharmaceuticals Ltd., an Indian pharmaceutical firm, launched a glycopyrrolate injection approved by the FDA. This medication serves as a pre-operative antimuscarinic, reducing salivary, tracheobronchial, and pharyngeal secretions while lowering gastric secretions' volume and acidity. This cost-effective solution expands access to reliable treatment options for healthcare providers and patients, showcasing Alembic's commitment to affordable healthcare solutions.

In May 2022, Halozyme Therapeutics Inc., a US biotechnology company, acquired Antares Pharma Inc. for $960 million. This acquisition aims to enhance Antares Pharma Inc.'s portfolio of self-administered parenteral pharmaceutical products and technologies, specifically focusing on improving drug delivery systems such as self-injection devices and formulations. Antares Pharma Inc., based in the US, specializes in producing compounds for anticholinergic drugs.

Major companies operating in the anticholinergic drugs market are Pfizer Inc., Abbvie Inc., Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Macleods Pharmaceuticals Ltd., Perrigo Company plc, Aurobindo Pharma Limited, Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals plc, Endo International plc, Lupin Limited, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, Indivior plc, Hisamitsu Pharmaceutical Co. Inc., Viatris Inc., Cogentix Medical Inc.

North America was the largest region in the anticholinergic drugs market in 2023. Asia- Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anticholinergic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the anticholinergic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anticholinergic drugs market consists of sales of antispasmodics, overactive bladder agents, bronchodilators, anti-Parkinson agents, motion sickness medications, and mydriatics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.